Apichope Pharmaceutical Group Co.,Ltd. has voluntarily disclosed that its gout innovation drug AR882 has achieved the primary endpoint in a Phase III clinical study for treating gout patients with hyperuricemia.

As the core product in Apichope's chronic disease innovation pipeline, the clinical progress and commercialization potential of AR882 (deupirfenidone), a next-generation highly selective urate transporter 1 (URAT1) inhibitor, have been a focal point for capital markets. We apply the industry-standard risk-adjusted net present value (rNPV) model, incorporating public clinical data, competitive landscape, and commercialization expectations, to estimate the pipeline's intrinsic value and provide a valuation reference for the market.

The core logic of rNPV valuation involves discounting the pipeline's full lifecycle cash flows to the present after multiple risk adjustments. The formula is: peak sales × clinical success probability × discount factor. Peak sales equate to: total target patient population × expected peak penetration rate × market share × annual treatment cost × clinical data quality coefficient × commercialization rights coefficient.

Regarding clinical success probability, AR882's domestic Phase III registration trial for gout with hyperuricemia recently released topline results. The 75mg group achieved an 86.0% response rate for serum uric acid <360μmol/L after 24 weeks of treatment, significantly outperforming the febuxostat 40mg group (P<0.001). Key efficacy indicators, including the uric acid target achievement rate and low uric acid response rate, met predefined goals. Safety data remained consistent with earlier studies, with no new safety signals. The program has now entered data cleaning and NDA preparation, with submission expected between late 2026 and early 2027. Based on industry-recognized clinical success rate grading standards, the clinical success probability is set at 0.70.

For total patient population, AR882 primarily targets gout patients requiring systemic urate-lowering therapy. According to public industry data and clinical guidelines, China's total gout patient population is approximately 38 million. For penetration rate, the peak penetration rate in this calculation refers to the long-term steady-state penetration of the entire URAT1 inhibitor category among domestic gout patients requiring systemic treatment, measuring the category's mature development stage. Based on the current gout treatment baseline in China, the overall standardized urate-lowering treatment rate remains low, with approximately 25% of moderate-to-severe target patients with long-term treatment indications receiving therapy. Drawing on the treatment rate improvement paths of mature chronic diseases like hypertension and diabetes, combined with increased gout awareness, improved medical insurance coverage, and continued clinical guideline promotion, the standardized treatment rate for target patients is expected to rise to approximately 35% in the long term.

Regarding category substitution potential, the current domestic urate-lowering drug market remains dominated by traditional xanthine oxidase inhibitors such as allopurinol and febuxostat, accounting for over 80% of the market. As a next-generation highly selective urate-lowering drug, URAT1 inhibitors offer clear differentiated advantages in urate-lowering intensity, tophus dissolution, and hepatic/renal safety. With the launch of domestic alternatives, price reductions, and growing clinical awareness, the category is expected to capture approximately 25% of the target patients' standardized treatment regimens at long-term steady state. Combining treatment rate improvement and category substitution factors, the long-term steady-state peak penetration rate for URAT1 inhibitors among domestic gout target patients is approximately 8.8%, rounded to 9% for calculation purposes.

For market share, the domestic URAT1 inhibitor landscape already includes Eisai's dotinurad and Hengrui Pharmaceutical's luzunorena on the market, while similar products from companies like InveniBio and New Element Medicine are in Phase III trials, representing a red-ocean competitive environment for domestic innovative drugs. Considering the competitive landscape, Apichope's chronic disease commercialization capabilities, and AR882's differentiated clinical advantages in urate-lowering intensity and tophus dissolution, a market share assumption of approximately 20% is assigned to AR882.

For annual treatment cost, following the 2025 national medical insurance negotiation, dotinurad tablets saw substantial price reductions. At the average clinical dosage, the post-insurance annual treatment cost is approximately 2,000 yuan. Domestic URAT1 inhibitors generally adopt differentiated pricing strategies, with prices varying based on clinical value relative to the original drug. Considering AR882 is a domestic innovative drug with head-to-head superiority over standard therapy and differentiated clinical value in promoting tophus dissolution, while also needing to align with medical insurance payment systems and market competition, its post-insurance annual treatment cost is estimated at approximately 3,000 yuan.

On clinical data quality, based on the Phase III data disclosed by Apichope, the randomized double-blind controlled trial of AR882 for gout with hyperuricemia demonstrated overall efficacy superior to existing standard treatment, with differentiated advantages in long-term safety and tophus dissolution. Therefore, the clinical data quality coefficient is set at 1.0. For commercialization rights, AR882 is a Class 1 innovative drug independently developed by Apichope, holding complete development, manufacturing, and commercialization rights in Greater China. Apichope also possesses a mature proprietary chronic disease commercialization team, eliminating the need for external sales royalty payments. According to evaluation standards, the commercialization rights coefficient is set at 0.95.

Based on the above parameters, AR882's peak annual sales for the gout indication in Greater China are estimated at approximately 1.95 billion yuan. For the discount factor, as a pharmaceutical company with commercialized products and mature promotional capabilities, Apichope's pipeline risk is lower than early-stage biotech firms, corresponding to a 12% discount rate. From a timeline perspective, AR882 is expected to receive market approval around 2028. Innovative drugs typically require 5-7 years to reach peak sales after launch, with peak expected around 2034, approximately 8 years from the current point. Applying the compound discount formula, the discount factor is approximately 0.40. Combined with the 0.70 clinical success probability, the final rNPV for AR882's Greater China gout indication pipeline is approximately 550 million yuan.

Disclaimer: The peak sales and risk-adjusted net present value figures in this article are model calculations based on public information and a series of subjective assumptions. They are intended solely to illustrate the valuation logic and do not represent official forecasts from Apichope, nor do they constitute investment advice. Key parameters such as clinical success rate, penetration rate, market share, and annual treatment cost carry significant uncertainty, and actual results may differ materially from estimates. Investors should exercise independent judgment and assume their own investment risks.